Calamos Advisors LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 5.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,116,123 shares of the biopharmaceutical company’s stock after acquiring an additional 102,245 shares during the quarter. Calamos Advisors LLC’s holdings in Pfizer were worth $76,773,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. HC Financial Advisors Inc. acquired a new stake in Pfizer in the 4th quarter valued at approximately $2,685,000. Itau Unibanco Holding S.A. boosted its stake in Pfizer by 118.6% during the 4th quarter. Itau Unibanco Holding S.A. now owns 59,000 shares of the biopharmaceutical company’s stock valued at $2,137,000 after purchasing an additional 32,009 shares in the last quarter. Stevens First Principles Investment Advisors boosted its stake in Pfizer by 7.0% during the 4th quarter. Stevens First Principles Investment Advisors now owns 31,234 shares of the biopharmaceutical company’s stock valued at $1,131,000 after purchasing an additional 2,040 shares in the last quarter. Uncommon Cents Investing LLC bought a new position in Pfizer during the 4th quarter valued at $1,667,000. Finally, Afam Capital Inc. boosted its stake in Pfizer by 3.5% during the 4th quarter. Afam Capital Inc. now owns 87,558 shares of the biopharmaceutical company’s stock valued at $3,171,000 after purchasing an additional 2,928 shares in the last quarter. Hedge funds and other institutional investors own 69.14% of the company’s stock.

A number of equities analysts have issued reports on PFE shares. Credit Suisse Group increased their price target on Pfizer from $39.00 to $40.00 and gave the company a “neutral” rating in a research note on Wednesday, August 1st. Morgan Stanley set a $45.00 price target on Pfizer and gave the company a “buy” rating in a research note on Wednesday, August 29th. Bank of America increased their price target on Pfizer from $42.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, August 1st. JPMorgan Chase & Co. reaffirmed a “$37.66” rating on shares of Pfizer in a research note on Wednesday, July 18th. Finally, Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, July 15th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $41.89.

In other news, insider Sally Susman sold 40,381 shares of the stock in a transaction on Friday, July 20th. The stock was sold at an average price of $37.22, for a total value of $1,502,980.82. Following the completion of the sale, the insider now owns 155,377 shares in the company, valued at $5,783,131.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction on Monday, August 13th. The shares were sold at an average price of $41.00, for a total value of $418,774.00. Following the completion of the sale, the insider now owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The disclosure for this sale can be found here. Insiders sold 761,230 shares of company stock valued at $29,054,690 in the last 90 days. Corporate insiders own 0.06% of the company’s stock.

Shares of PFE traded up $0.11 during trading hours on Friday, hitting $42.96. 15,617,479 shares of the company were exchanged, compared to its average volume of 17,726,890. The firm has a market cap of $252.46 billion, a PE ratio of 16.21, a P/E/G ratio of 2.04 and a beta of 0.96. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41. Pfizer Inc. has a one year low of $33.20 and a one year high of $43.00.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.07. The business had revenue of $13.47 billion during the quarter, compared to analyst estimates of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The company’s revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company posted $0.67 EPS. equities research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 4th. Stockholders of record on Friday, August 3rd were issued a $0.34 dividend. The ex-dividend date of this dividend was Thursday, August 2nd. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.17%. Pfizer’s payout ratio is currently 51.32%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: How is a Moving Average Calculated?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.